A new medicine composition can succeed in treating “acute leukemia”

A recent clinical trial showed promising results for a new treatment aimed at acute sophisticated leukemia patients with specific genetic mutations. The results say that the integration of the medicine “rifominip”, which is aimed at traditional chemotherapy, has led to high healing rates and strong reactions, increasing the hope of developing a personal treatment approach, and effective for this complex type of cancer. “Ribuminib” is a new remedy to treat some types of acute blood cancer that contains a specific genetic defect, and this medicine is taken orally, and it works by preventing protein interaction in the body that contributes to the growth of these cancers. The US Food and Drug Administration agreed to use this mid-November 2024 after experiments that include 104 adults of adults and children of the age of 30 days or longer; This medicine is the first treatment of his class that depends on this new mechanism to fight cancer. “Minin”, which plays an important role in stimulating genes associated with the growth of cancer cells. When stimulating the death of the cancer cells. These two are often used for the treatment of acute pelvic leukemia, especially in the elderly. The participants did not monitor no indications of the presence of cancer cells after the treatment, while the full recovery rate reached 67.4%, which means that the disease has completely disappeared and the blood tests returned to their normal levels. 62.9% of patients live, which is a rate of more expectations compared to traditional treatment alone, especially since the survival rate for five years for this type of cancer is no more than 33%, and it drops to 17% between those who exceeded the age of sixty. A specialized European research, with the aim of testing whether these results can be distributed and a change in the treatment protocols. The character in the treatment is the future of oncology, especially in complex diseases such as leukemia, as uniform treatments are not sufficient for everyone. The safety of the new treatment, with the possibility of formally adopting in the near future as a basic therapeutic option.